No association between LDL receptor and genetic variants and atorvastatin response in Jordanian hyperlipidemic patients.

Objectives: Atorvastatin is commonly used medication to achieve low levels of low-density lipoproteins (LDL). Cholesteryl ester transfer protein () and LDL receptor () genetic variants can affect the cholesterol transport and hence may affect on atorvastatin response. This study aimed to investigate the influence of LDLR , and on the efficacy of 20 mg atorvastatin among Jordanian hyperlipidemic patients.

Methods: One hundred and 50 blood samples were collected from hyperlipidemic patients in the University of Jordan Hospital. Polymerase chain reaction-restriction fragment length polymorphism was used for genotyping of and genetic variants. The genotyping of variant was done by Sanger DNA-Sequencing.

Results: LDLR and and variants showed a significant (p value < 0.05) association with the baseline of the LDL at the time of diagnoses. On the other hand, none of the tested genetic variants showed a significant (p value>0.05) association with LDL reduction after atorvastatin therapy.

Conclusions: Results demonstrated a significant association between the and and genetic variants with the LDL baseline level. However, the atorvastatin therapy among hyperlipidemic patients of Jordanian origin was not affected by any of the tested variants.